Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 464

1.

In vivo acquisition and risk of inter-species spread of bla KPC-3-plasmid from Klebsiella pneumoniae to Serratia marcescens in the lower respiratory tract.

Bielli A, Piazza A, Cento V, Comandatore F, Lepera V, Gatti M, Brioschi P, Vismara C, Bandi C, Perno CF.

J Med Microbiol. 2020 Jan 6. doi: 10.1099/jmm.0.001113. [Epub ahead of print]

PMID:
31904319
2.

CMV infection management in transplant patients in Italy.

Grossi PA, Baldanti F, Andreoni M, Perno CF.

J Clin Virol. 2020 Feb;123:104211. doi: 10.1016/j.jcv.2019.104211. Epub 2019 Nov 9. Review.

PMID:
31879243
3.

Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort.

d'Arminio Monforte A, Tavelli A, Cozzi-Lepri A, Castagna A, Passerini S, Francisci D, Saracino A, Maggiolo F, Lapadula G, Girardi E, Perno CF, Antinori A; Icona Foundation Study Group .

J Antimicrob Chemother. 2019 Dec 22. pii: dkz512. doi: 10.1093/jac/dkz512. [Epub ahead of print]

PMID:
31865395
4.

HIV-1 viral load is elevated in individuals with reverse transcriptase mutation M184V/I during virological failure of first line antiretroviral therapy and is associated with compensatory mutation L74I.

Gregson J, Rhee SY, Datir R, Pillay D, Perno CF, Derache A, Shafer RS, Gupta RK.

J Infect Dis. 2019 Nov 27. pii: jiz631. doi: 10.1093/infdis/jiz631. [Epub ahead of print]

PMID:
31774913
5.

Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat".

Fokam J, Sosso SM, Yagai B, Billong SC, Djubgang Mbadie RE, Kamgaing Simo R, Edimo SV, Nka AD, Tiga Ayissi A, Yimga JF, Takou D, Moudourou S, Ngo Nemb M, Nfetam Elat JB, Santoro MM, Perno CF, Colizzi V, Ndjolo A.

AIDS Res Ther. 2019 Nov 19;16(1):36. doi: 10.1186/s12981-019-0252-0.

6.

Towards Rapid Sepsis Diagnosis and Patients Stratification: What's New From Microbiology and Omics Science.

Mangioni D, Peri AM, Rossolini GM, Viaggi B, Perno CF, Gori A, Bandera A.

J Infect Dis. 2019 Nov 6. pii: jiz585. doi: 10.1093/infdis/jiz585. [Epub ahead of print]

PMID:
31693109
7.

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: latest evidences from the literature on their efficacy and safety.

Cento V, Perno CF.

J Glob Antimicrob Resist. 2019 Aug 22. pii: S2213-7165(19)30208-5. doi: 10.1016/j.jgar.2019.08.010. [Epub ahead of print] Review.

PMID:
31446092
8.

Tuberculosis among asylum seekers in Milan, Italy: epidemiological analysis and evaluation of interventions.

Villa S, Codecasa LR, Faccini M, Pontello MM, Ferrarese M, Castellotti PF, Senatore S, Lamberti A, Mazzola E, Perno CF, Campisi D, Saporiti M, Raviglione MC.

Eur Respir J. 2019 Oct 31;54(4). pii: 1900896. doi: 10.1183/13993003.00896-2019. Print 2019 Oct.

PMID:
31413161
9.

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.

Scutari R, Alteri C, Vicenti I, Di Carlo D, Zuccaro V, Incardona F, Borghi V, Bezenchek A, Andreoni M, Antinori A, Perno CF, Cascio A, De Luca A, Zazzi M, Santoro MM; ARCA (Antiviral Response Cohort Analysis) Study Group.

J Glob Antimicrob Resist. 2019 Jul 19;20:163-169. doi: 10.1016/j.jgar.2019.07.015. [Epub ahead of print]

PMID:
31330378
10.

Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy: a study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study).

Fokam J, Santoro MM, Takou D, Njom-Nlend AE, Ndombo PK, Kamgaing N, Kamta C, Essiane A, Sosso SM, Ndjolo A, Colizzi V, Perno CF.

BMC Pediatr. 2019 Jul 5;19(1):226. doi: 10.1186/s12887-019-1599-z.

11.

NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients.

Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F.

Cells. 2019 Jul 2;8(7). pii: E666. doi: 10.3390/cells8070666.

12.

Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage.

Borrajo A, Ranazzi A, Pollicita M, Bellocchi MC, Salpini R, Mauro MV, Ceccherini-Silberstein F, Perno CF, Svicher V, Aquaro S.

Medicina (Kaunas). 2019 Jun 21;55(6). pii: E297. doi: 10.3390/medicina55060297.

13.

Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success.

Alteri C, Scutari R, Stingone C, Maffongelli G, Brugneti M, Falasca F, Martini S, Bertoli A, Turriziani O, Sarmati L, Coppola N, Andreoni M, Santoro MM, Perno CF, Ceccherini-Silberstein F, Svicher V.

J Clin Virol. 2019 Aug;117:61-67. doi: 10.1016/j.jcv.2019.06.004. Epub 2019 Jun 14.

PMID:
31229934
14.

Collaborative national multicenter for the identification of conversion factors from copies/mL to international units/mL for the normalization of HCMV DNA load.

Sidoti F, Piralla A, Costa C, Scarasciulli ML, Calvario A, Conaldi PG, Paba P, Perno CF, Gaeta A, Antonelli G, Sodano G, Santangelo R, Sanguinetti M, Vatteroni ML, Barzon L, Palù G, Abbate I, Capobianchi MR, Piccirilli G, Lazzarotto T, Baldanti F, Cavallo R.

Diagn Microbiol Infect Dis. 2019 Oct;95(2):152-158. doi: 10.1016/j.diagmicrobio.2019.05.012. Epub 2019 May 25.

PMID:
31204110
15.

HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma.

Sorbo MC, Carioti L, Bellocchi MC, Antonucci F, Sforza D, Lenci I, Ciancio Manuelli M, Armenia D, De Leonardis F, Milana M, Manzia TM, Angelico M, Tisone G, Cento V, Perno CF, Ceccherini-Silberstein F.

Liver Int. 2019 Oct;39(10):1986-1998. doi: 10.1111/liv.14168. Epub 2019 Jul 16.

PMID:
31172639
16.

Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy.

Fabeni L, Alteri C, Berno G, Scutari R, Orchi N, De Carli G, Bertoli A, Carioti L, Gori C, Forbici F, Salpini R, Vergori A, Gagliardini R, Cicalini S, Mondi A, Pinnetti C, Mazzuti L, Turriziani O, Colafigli M, Borghi V, Montella F, Pennica A, Lichtner M, Girardi E, Andreoni M, Mussini C, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM; SENDIH Study group.

Sex Transm Infect. 2019 Dec;95(8):619-625. doi: 10.1136/sextrans-2019-054017. Epub 2019 May 10.

PMID:
31076456
17.

Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.

Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group.

Antivir Ther. 2019;24(5):321-331. doi: 10.3851/IMP3309.

18.

A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection.

Salpini R, Battisti A, Colagrossi L, Di Carlo D, Fabeni L, Piermatteo L, Cerva C, Lichtner M, Mastroianni C, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Angelico M, Sarmati L, Andreoni M, Perno CF, Ceccherini-Silberstein F, Svicher V.

J Viral Hepat. 2019 Jul;26(7):846-855. doi: 10.1111/jvh.13101. Epub 2019 May 14.

PMID:
30974483
19.

HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.

Takou D, Fokam J, Teto G, Santoro MM, Ceccherini-Silberstein F, Nanfack AJ, Sosso SM, Dambaya B, Salpini R, Billong SC, Gori C, Fokunang CN, Cappelli G, Colizzi V, Perno CF, Ndjolo A.

BMC Infect Dis. 2019 Mar 12;19(1):246. doi: 10.1186/s12879-019-3871-0.

20.

Combined evaluation of genotype and phenotype of thiopurine S-methyltransferase (TPMT) in the clinical management of patients in chronic therapy with azathioprine.

Rucci F, Cigoli MS, Marini V, Fucile C, Mattioli F, Robbiano L, Cavallari U, Scaglione F, Perno CF, Penco S, Marocchi A.

Drug Metab Pers Ther. 2019 Mar 6;34(1). pii: /j/dmdi.2019.34.issue-1/dmpt-2018-0037/dmpt-2018-0037.xml. doi: 10.1515/dmpt-2018-0037.

PMID:
30840585
21.

Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?

Moreno S, Perno CF, Mallon PW, Behrens G, Corbeau P, Routy JP, Darcis G.

HIV Med. 2019 Apr;20 Suppl 4:2-12. doi: 10.1111/hiv.12716. Review.

PMID:
30821898
22.

Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice.

Alteri C, Scutari R, Bertoli A, Armenia D, Gori C, Fabbri G, Mastroianni CM, Cerva C, Cristaudo A, Vicenti I, Bruzzone B, Zazzi M, Andreoni M, Antinori A, Svicher V, Ceccherini-Silberstein F, Perno CF, Santoro MM.

Virus Genes. 2019 Jun;55(3):290-297. doi: 10.1007/s11262-019-01649-z. Epub 2019 Feb 22.

PMID:
30796743
23.

Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients.

Antinori A, Santoro MM, Gagliardini R, Marchetti G, Mondi A, Cento V, Perno CF, Andreoni M; Two-Drug Antiretroviral Regimens expert panel.

New Microbiol. 2019 Apr;42(2):69-80. Epub 2019 Feb 20. Review.

24.

The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic Clinical Management of HIV-1 Infected Persons.

Guaraldi G, Marcotullio S, Maserati R, Gargiulo M, Milic J, Franconi I, Chirianni A, Andreoni M, Galli M, Lazzarin A, D'Arminio Monforte A, Di Perri G, Perno CF, Puoti M, Vella S, Di Biagio A, Maia L, Mussi C, Cesari M, Antinori A.

J Frailty Aging. 2019;8(1):10-16. doi: 10.14283/jfa.2018.42.

PMID:
30734825
25.

Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.

Antinori A, Di Biagio A, Marcotullio S, Sarmati L, Andreoni M, Angarano G, Chirianni A, d'Arminio Monforte A, Di Perri G, Galli M, Gianotti N, Girardi E, Gori A, Mussini C, Perno CF, Lazzarin A.

New Microbiol. 2018 Oct;41(4):247-255. Review.

26.

Real life experiences in HCV management in 2018.

Viganò M, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagiuoli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL.

Expert Rev Anti Infect Ther. 2019 Feb;17(2):117-128. doi: 10.1080/14787210.2019.1563755. Epub 2019 Jan 15. Review.

PMID:
30582384
27.

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.

Soulie C, Santoro MM, Charpentier C, Storto A, Paraskevis D, Di Carlo D, Gennari W, Sterrantino G, Zazzi M, Perno CF, Calvez V, Descamps D, Ceccherini-Silberstein F, Marcelin AG.

J Antimicrob Chemother. 2019 Mar 1;74(3):614-617. doi: 10.1093/jac/dky464.

PMID:
30476106
28.

The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro.

Salpini R, Surdo M, Cortese MF, Palumbo GA, Carioti L, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Pasquazzi C, Mirabelli C, Scutari R, Sacco A, Alkhatib M, Missale G, Francioso S, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, Svicher V.

Clin Microbiol Infect. 2019 Jul;25(7):906.e1-906.e7. doi: 10.1016/j.cmi.2018.11.017. Epub 2018 Nov 23.

PMID:
30472417
29.

Viral resistance in HCV infection.

Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A.

Curr Opin Virol. 2018 Oct;32:115-127. doi: 10.1016/j.coviro.2018.10.005. Epub 2018 Nov 12. Review.

PMID:
30439589
30.

Different kinetics of viral replication and DNA integration in the main HIV-1 cellular reservoirs in the presence and absence of integrase inhibitors.

Surdo M, Cortese MF, Orlandi C, Di Santo F, Aquaro S, Magnani M, Perno CF, Casabianca A, Ceccherini-Silberstein F.

Antiviral Res. 2018 Dec;160:165-174. doi: 10.1016/j.antiviral.2018.10.017. Epub 2018 Oct 26.

PMID:
30420339
31.

A three-in-one, long-acting, nanosuspension reformulation of off-patent antiretrovirals for low-income and middle-income countries.

Cattaneo D, Perno CF, Rizzardini G.

AIDS. 2018 Nov 13;32(17):2625-2627. doi: 10.1097/QAD.0000000000001970. No abstract available.

PMID:
30379688
32.

Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence.

Alteri C, Fabeni L, Scutari R, Berno G, Di Carlo D, Gori C, Bertoli A, Vergori A, Mastrorosa I, Bellagamba R, Mussini C, Colafigli M, Montella F, Pennica A, Mastroianni CM, Girardi E, Andreoni M, Antinori A, Svicher V, Ceccherini-Silberstein F, Perno CF, Santoro MM.

Sci Rep. 2018 Oct 24;8(1):15739. doi: 10.1038/s41598-018-34058-7.

33.

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART.

Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group.

J Antimicrob Chemother. 2018 Dec 1;73(12):3460-3470. doi: 10.1093/jac/dky350.

34.

New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T).

Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, Alcaro S, Antinori A, Wirden M, Perno CF, Ambrosio FA, Calvez V, Descamps D, Marcelin AG, Ceccherini-Silberstein F, Lambert-Niclot S.

Chem Biol Drug Des. 2019 Jan;93(1):50-59. doi: 10.1111/cbdd.13378. Epub 2018 Nov 27.

PMID:
30103267
35.

HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets.

Colagrossi L, Salpini R, Scutari R, Carioti L, Battisti A, Piermatteo L, Bertoli A, Fabeni L, Minichini C, Trimoulet P, Fleury H, Nebuloso E, De Cristofaro M, Cappiello G, Spanò A, Malagnino V, Mari T, Barlattani A, Iapadre N, Lichtner M, Mastroianni C, Lenci I, Pasquazzi C, De Sanctis GM, Galeota Lanza A, Stanzione M, Stornaiuolo G, Marignani M, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Perno CF, Coppola N, Svicher V.

Viruses. 2018 Jul 9;10(7). pii: E363. doi: 10.3390/v10070363.

36.

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.

Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C).

Sci Rep. 2018 Jun 12;8(1):8988. doi: 10.1038/s41598-018-26862-y.

37.

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.

Colagrossi L, Hermans LE, Salpini R, Di Carlo D, Pas SD, Alvarez M, Ben-Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Lepej SZ, Weis N, Yalcinkaya T, Boucher CAB, Wensing AMJ, Perno CF, Svicher V; HEPVIR working group of the European Society for translational antiviral research (ESAR).

BMC Infect Dis. 2018 Jun 1;18(1):251. doi: 10.1186/s12879-018-3161-2.

38.

Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment.

Borderi M, Angarano G, Antinori A, Chirianni A, Cinque P, D'Arminio Monforte A, Di Biagio A, Di Perri G, Galli M, Gori A, Lazzarin A, Mussini C, Perno CF, Quirino T, Rizzardini G, Calza L, Viale P, Acone B, Andreoni M.

New Microbiol. 2018 Apr;41(2):112-117.

39.

HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals.

Guardigni V, Cento V, Ianniruberto S, Badia L, Aragri M, Conti M, Perno CF, Viale P, Ceccherini-Silberstein F, Verucchi G.

Infection. 2018 Oct;46(5):717-720. doi: 10.1007/s15010-018-1158-9. Epub 2018 May 26.

PMID:
29804205
40.

The degree of HIV-1 amino acid variability is strictly related to different disease progression rates.

Scutari R, Faieta M, D'Arrigo R, Fabeni L, Mussini C, Cossarizza A, Casoli C, Perno CF, Svicher V, Alteri C, Aquaro S.

Virus Genes. 2018 Aug;54(4):493-501. doi: 10.1007/s11262-018-1571-2. Epub 2018 May 17.

PMID:
29777446
41.

Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study.

Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, Gasbarrini A, Taliani G, Attili AF, Perno CF, De Santis A, Puro V, Cerqua F, D'Offizi G, Pellicelli A, Armignacco O, Mennini FS, Siciliano M, Girardi E, Panella V, Ippolito G; members of the Lazio Region HCV treatment group.

BMC Infect Dis. 2018 May 16;18(1):223. doi: 10.1186/s12879-018-3125-6.

42.

Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.

Armenia D, Zaccarelli M, Borghi V, Gennari W, Di Carlo D, Giannetti A, Forbici F, Bertoli A, Gori C, Fabeni L, Pinnetti C, Marocco R, Latini A, Ceccherini-Silberstein F, Mastroianni CM, Mussini C, Antinori A, Perno CF, Santoro MM.

J Clin Virol. 2018 Jul;104:61-64. doi: 10.1016/j.jcv.2018.04.001. Epub 2018 Apr 3.

PMID:
29738896
43.

Corrigendum to "Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018" [Drug Resist. Updates 37 (March) (2018) 17-39].

Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F.

Drug Resist Updat. 2018 Sep;40:40-41. doi: 10.1016/j.drup.2018.04.001. Epub 2018 Apr 19. No abstract available.

PMID:
29680499
44.

High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance.

Malagnino V, Salpini R, Maffongelli G, Battisti A, Fabeni L, Piermatteo L, Colagrossi L, Fini V, Ricciardi A, Sarrecchia C, Perno CF, Andreoni M, Svicher V, Sarmati L.

PLoS One. 2018 Mar 29;13(3):e0195045. doi: 10.1371/journal.pone.0195045. eCollection 2018.

45.

Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children.

Fokam J, Bellocchi MC, Armenia D, Nanfack AJ, Carioti L, Continenza F, Takou D, Temgoua ES, Tangimpundu C, Torimiro JN, Koki PN, Fokunang CN, Cappelli G, Ndjolo A, Colizzi V, Ceccherini-Silberstein F, Perno CF, Santoro MM.

Medicine (Baltimore). 2018 Mar;97(13):e0176. doi: 10.1097/MD.0000000000010176.

46.

Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients.

Lazzarotto T, Chiereghin A, Piralla A, Piccirilli G, Girello A, Campanini G, Gabrielli L, Costa C, Prete A, Bonifazi F, Busca A, Cairoli R, Colombo AA, Zecca M, Sidoti F, Bianco G, Paba P, Perno CF, Cavallo R, Baldanti F; AMCLI-GLaIT working group.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1699-1706. doi: 10.1016/j.bbmt.2018.03.005. Epub 2018 Mar 12.

47.

Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.

Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F.

Drug Resist Updat. 2018 Mar;37:17-39. doi: 10.1016/j.drup.2018.01.004. Epub 2018 Feb 21. Review. Erratum in: Drug Resist Updat. 2018 Apr 18;:.

PMID:
29525636
48.

Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.

Quercia R, Perno CF, Koteff J, Moore K, McCoig C, St Clair M, Kuritzkes D.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):125-135. doi: 10.1097/QAI.0000000000001660. Review.

49.

Cytomegalovirus Glycoprotein B Genotype Distribution in Italian Transplant Patients.

Ciotti M, Cella E, Rittà M, Ciccozzi M, Cavallo R, Perno CF, Costa C.

Intervirology. 2017;60(4):165-170. doi: 10.1159/000486593. Epub 2018 Feb 2.

50.

Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy.

Brancaccio G, Sorbo MC, Frigeri F, Rizzo V, Cantone M, Genderini F, Fabeni L, Pinto A, Perno CF, Ceccherini-Silberstein F, Gaeta GB.

Clin Gastroenterol Hepatol. 2018 Jun;16(6):977-978. doi: 10.1016/j.cgh.2017.10.032. Epub 2017 Nov 28. No abstract available.

PMID:
29104131

Supplemental Content

Loading ...
Support Center